Biogenics (India) Profile
Key Indicators
- Authorised Capital ₹ 3.64 Cr
as on 29-12-2024
- Paid Up Capital ₹ 3.51 Cr
as on 29-12-2024
- Company Age 53 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.14 M
as on 29-12-2024
- Satisfied Charges ₹ 2.94 Cr
as on 29-12-2024
- Revenue %
(FY 2022)
- Profit 43.93%
(FY 2022)
- Ebitda 0.01%
(FY 2022)
- Net Worth -0.94%
(FY 2022)
- Total Assets %
(FY 2022)
About Biogenics (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.64 Cr and a paid-up capital of Rs 3.51 Cr.
The company currently has active open charges totaling ₹8.14 M. The company has closed loans amounting to ₹2.94 Cr, as per Ministry of Corporate Affairs (MCA) records.
Gulshan Bhatia, Hiten Ramchandani, and Hitesh Ramchandani serve as directors at the Company.
- CIN/LLPIN
U24230MH1971PLC015378
- Company No.
015378
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Oct 1971
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biogenics (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gulshan Bhatia  | Director | 03-Jun-2015 | Current |
| Hiten Ramchandani | Director | 03-Jun-2015 | Current |
| Hitesh Ramchandani | Director | 15-Jul-2014 | Current |
Financial Performance of Biogenics (India).
Biogenics (India) Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 43.93% increase in profit. The company's net worth dipped by a decrease of 0.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biogenics (India)?
In 2022, Biogenics (India) had a promoter holding of 95.00% and a public holding of 5.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Air Pac Filters And Systems Private LimitedActive 33 years 10 monthsHiten Ramchandani is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Saraswat Co- Op. Bank Ltd. Creation Date: 18 May 1990 | ₹3.84 M | Open |
The Saraswat Co- Op. Bank Ltd. Creation Date: 21 Sep 1989 | ₹0.10 M | Open |
The Saraswat Co- Op. Bank Ltd. Creation Date: 30 Dec 1988 | ₹0.48 M | Open |
How Many Employees Work at Biogenics (India)?
Unlock and access historical data on people associated with Biogenics (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biogenics (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biogenics (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
